Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
University of Kentucky College of Medicine
mi
from
Lexington, KY
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
University of Kentucky College of Medicine
mi
from
Lexington, KY
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Montgomery Cancer Center
mi
from
Mt. Sterling, KY
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Montgomery Cancer Center
mi
from
Mt. Sterling, KY
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Mayo Clinic Rochester
mi
from
Rochester, MN
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Hattiesburg Clinic
mi
from
Hattiesburg, MS
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Hattiesburg Clinic
mi
from
Hattiesburg, MS
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Jackson Oncology Associates
mi
from
Jackson, MS
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Jackson Oncology Associates
mi
from
Jackson, MS
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Hackensack University Medical Center
mi
from
Hackensack, NJ
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
St. Vincents Comprehensive Cancer Center
mi
from
New York, NY
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
St. Vincents Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Summa Health System
mi
from
Akron, OH
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Summa Health System
mi
from
Akron, OH
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Gabrail Cancer Center
mi
from
Canton, OH
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Cleveland Clinic
mi
from
Cleveland, OH
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Dayton Clinical Oncology Program
mi
from
Dayton, OH
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Dayton Clinical Oncology Program
mi
from
Dayton, OH
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Harrington Cancer Center
mi
from
Amarillo, TX
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Harrington Cancer Center
mi
from
Amarillo, TX
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Texas Oncology Cancer Center
mi
from
Austin, TX
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Texas Oncology Cancer Center
mi
from
Austin, TX
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
University of Calgary
mi
from
Calgary,
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
University of Calgary
mi
from
Calgary,
Click here to add this to my saved trials
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients With Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)
Status: Enrolling
Updated:  10/29/2015
GSK Investigational Site
mi
from
Aurora, CO
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients With Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)
Status: Enrolling
Updated: 10/29/2015
GSK Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients With Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)
Status: Enrolling
Updated:  10/29/2015
GSK Investigational Site
mi
from
Tuscon, AZ
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients With Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)
Status: Enrolling
Updated: 10/29/2015
GSK Investigational Site
mi
from
Tuscon, AZ
Click here to add this to my saved trials
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients With Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)
Status: Enrolling
Updated:  10/29/2015
GSK Investigational Site
mi
from
Fort Myers, FL
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients With Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)
Status: Enrolling
Updated: 10/29/2015
GSK Investigational Site
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients With Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)
Status: Enrolling
Updated:  10/29/2015
GSK Investigational Site
mi
from
St. Petersburg, FL
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients With Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)
Status: Enrolling
Updated: 10/29/2015
GSK Investigational Site
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients With Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)
Status: Enrolling
Updated:  10/29/2015
GSK Investigational Site
mi
from
Nashville, TN
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients With Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)
Status: Enrolling
Updated: 10/29/2015
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients With Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)
Status: Enrolling
Updated:  10/29/2015
GSK Investigational Site
mi
from
Ogden, UT
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients With Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)
Status: Enrolling
Updated: 10/29/2015
GSK Investigational Site
mi
from
Ogden, UT
Click here to add this to my saved trials
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients With Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)
Status: Enrolling
Updated:  10/29/2015
GSK Investigational Site
mi
from
Bruxelles,
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients With Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)
Status: Enrolling
Updated: 10/29/2015
GSK Investigational Site
mi
from
Bruxelles,
Click here to add this to my saved trials
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage
Status: Enrolling
Updated:  10/29/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage
Status: Enrolling
Updated: 10/29/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage
Status: Enrolling
Updated:  10/29/2015
The Mayo Clinic
mi
from
Rochester, MN
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage
Status: Enrolling
Updated: 10/29/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
CD45A-Depleted Haploidentical Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
Status: Enrolling
Updated:  10/29/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
CD45A-Depleted Haploidentical Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
Status: Enrolling
Updated: 10/29/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated:  10/29/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated: 10/29/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated:  10/29/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated: 10/29/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated:  10/29/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated: 10/29/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated:  10/29/2015
Weil Medical College of Cornell University
mi
from
New York, NY
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated: 10/29/2015
Weil Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated:  10/29/2015
Herbert Irving Comprehensive Cancer Center of Columbia University
mi
from
New York, NY
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated: 10/29/2015
Herbert Irving Comprehensive Cancer Center of Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia
Status: Enrolling
Updated:  10/30/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia
Status: Enrolling
Updated: 10/30/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant
Maintenance Therapy With Thalidomide, Dexamethasone and Clarithromycin (Biaxin) Following Autologous/Syngeneic Transplant for Multiple Myeloma
Status: Enrolling
Updated:  10/30/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant
Maintenance Therapy With Thalidomide, Dexamethasone and Clarithromycin (Biaxin) Following Autologous/Syngeneic Transplant for Multiple Myeloma
Status: Enrolling
Updated: 10/30/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Cord Blood Expansion on Mesenchymal Stem Cells
Cord Blood Expansion on Mesenchymal Stem Cells
Status: Enrolling
Updated:  11/2/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Cord Blood Expansion on Mesenchymal Stem Cells
Cord Blood Expansion on Mesenchymal Stem Cells
Status: Enrolling
Updated: 11/2/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies
A Phase II Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) Plus Dexamethasone & Choline Magnesium Trisalicylate in the Treatment of Patients With Relapsed/Refractory Acute Myelogenous Leukemia
Status: Enrolling
Updated:  11/2/2015
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies
A Phase II Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) Plus Dexamethasone & Choline Magnesium Trisalicylate in the Treatment of Patients With Relapsed/Refractory Acute Myelogenous Leukemia
Status: Enrolling
Updated: 11/2/2015
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
Phase 2 Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
Status: Enrolling
Updated:  11/2/2015
Medical University of South Carolina
mi
from
Charleston, SC
Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
Phase 2 Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
Status: Enrolling
Updated: 11/2/2015
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
Phase 2 Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
Status: Enrolling
Updated:  11/2/2015
Greenville Hospital System
mi
from
Greenville, SC
Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
Phase 2 Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
Status: Enrolling
Updated: 11/2/2015
Greenville Hospital System
mi
from
Greenville, SC
Click here to add this to my saved trials
Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
A Phase I Study of the Hsp90 Inhibitor 17-DMAG (Alvespimycin) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), and B-cell Prolymphocytic Leukemia (B-PLL)
Status: Enrolling
Updated:  11/3/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
A Phase I Study of the Hsp90 Inhibitor 17-DMAG (Alvespimycin) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), and B-cell Prolymphocytic Leukemia (B-PLL)
Status: Enrolling
Updated: 11/3/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
Conditioning for Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies
Status: Enrolling
Updated:  11/3/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
Conditioning for Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies
Status: Enrolling
Updated: 11/3/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome
Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome.
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Rochester, MN
Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome
Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome.
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome
Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome.
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Houston, TX
Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome
Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome.
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated:  11/4/2015
Massachusetts General Hospital
mi
from
Boston, MA
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated: 11/4/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated:  11/4/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated: 11/4/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated:  11/4/2015
Prince of Wales Hospital
mi
from
Randwick,
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated: 11/4/2015
Prince of Wales Hospital
mi
from
Randwick,
Click here to add this to my saved trials
Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients
Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia (CML) on Imatinib, Dasatinib, Nilotinib (or Any Other FDA Approved TKI for CML)
Status: Enrolling
Updated:  11/4/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients
Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia (CML) on Imatinib, Dasatinib, Nilotinib (or Any Other FDA Approved TKI for CML)
Status: Enrolling
Updated: 11/4/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated:  11/6/2015
University of Colorado Cancer Center at UC Health Sciences Center
mi
from
Aurora, CO
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated: 11/6/2015
University of Colorado Cancer Center at UC Health Sciences Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated:  11/6/2015
Presbyterian/St. Luke's Medical Center (PSLMC) - Denver Midtown
mi
from
Denver, CO
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated: 11/6/2015
Presbyterian/St. Luke's Medical Center (PSLMC) - Denver Midtown
mi
from
Denver, CO
Click here to add this to my saved trials
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
Evaluation of Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide in Patients With Relapsed and Refractory Myeloma
Status: Enrolling
Updated:  11/6/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
Evaluation of Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide in Patients With Relapsed and Refractory Myeloma
Status: Enrolling
Updated: 11/6/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials